Clinical Trial Update: Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dosimetry study of I-131-CLR1404 in patients with relapsed or refractory advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• I-131-CLR1404 (Iodine-131 labeled CLR1404)

Snippet

Sponsor: Cellectar, Inc | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED